Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity

By /

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing convenience and efficacy.

Scroll to Top